The 5th Brain Tumors: From Biology to Therapy Conference
JUNE 22-24, 2022 the Nencki Institute, Warsaw, Pasteur 3 str.
CONFERENCE PROGRAM – DAY 1
WEDNESDAY, June 22, 2022
| 11:00–13:00 | Registration and welcome coffee | |
| 13:00–14:00 | Keynote lecture:
John de Groot, MD Anderson Cancer Center, USA The future of immunotherapy for glioma |
|
| 14:00–17:20 | Brain tumor pathobiology (chairs: Dolores Hambardzumyan, Bozena Kaminska) |
|
| 14:00–14:35 | Constantinos G. Hadjipanayis, Icahn School of Medicine at Mount Sinai, USA
Fluorescence-guided surgery and photodynamic therapy of brain tumors: a new combination |
|
| 14:35–15:10 | Martin van den Bent, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
The landscape of clinical trial in glioma: recently completed and ongoing projects |
|
| 15:10–15:40 | Coffee break | |
| 15:40–16:15 | Oren Becher, Mount Sinai Icahn School of Medicine, USA
Cellular heterogeneity in diffuse midline gliomas |
|
| 16:15–16.50 | Jacek Majewski, McGill University, CanadaEpigenomic landscapes of H3K27M mutant gliomas | |
| 16.50-17.20 | Oral presentations (3×10 min) | |
| 17:20–18:50 | Poster session part I | |
| 19:00–21:00 | Welcome reception |
CONFERENCE PROGRAM – DAY 2
THURSDAY, June 23, 2022
| 09:00–12:25 | Glioma microenvironment, immunology and immunotherapy I (chairs: Christel Herold-Mende, Aleksandra Ellert-Miklaszewska) |
|
| 09:00–9:35 | Bozena Kaminska, Nencki Institute, Warsaw, Poland
Immune microenvironment of glioma at single cell resolution |
|
| 09:35–10:10 | Dolores Hambardzumyan (Icahn School of Medicine, Mount Sinai, USA)
Glioblastoma subtype-specific heterogeneity of the immune microenvironment |
|
| 10:10–10:40 | Coffee break | |
| 10:40–11:15 | Katrin Lamszus (Universitätsklinikum Hamburg-Eppendorf; Hamburg, Germany)Cancer immunoediting in malignant glioma – interactions between immune cells and tumor cells | |
| 11:15–11:50 | Dieter Henrik Heiland, University of Freiburg, Germany
Spatiotemporal dynamics in the structural immunity of the glioblastoma microenvironment |
|
| 11:50–12.25 | Christel Herold-Mende, University of Heidelberg, Germany
Determinants of immune cell infiltration and immune responses in brain tumors |
|
| 12:25–13:25 | Lunch break | |
| 13:25–18:00 | Brain tumor microenvironment, immunology and immunotherapy II (chairs: Dinorah Friedman-Morvinski, Wiesława Grajkowska) |
|
| 13:25–14:00 | Alessandro Michelucci, Neuro-Immunology Group, Department of Oncology, Luxembourg Institute of Health, LuxembourgRevealing and harnessing tumor-associated microglia/macrophage heterogeneity in glioblastoma | |
| 14:00–14:35 | Waldemar Debinski, Wake Forest School of Medicine, USA
Novel targeted drug candidates for GBM treatment |
|
| 14:35–15:10 | Dinorah Friedmann-Morvinski, Tel Aviv University, Israel
Boosting CAR T cell efficacy by modulation of the microenvironment in brain tumors |
|
| 15:10–15:35 | Coffee break | |
| 15:35–16:10 | Houtan Noushmehr, Henry Ford Cancer Institute, USA
Advances in epigenomic classification and liquid biopsy in glioma |
|
| 16:10–16:45 | Neta Erez, Tel Aviv University, Israel
Systemic instigation of neuroinflammation facilitates brain metastasis |
|
| 16:45–17:20 | Hai-kun Liu, German Cancer Research Center (DKFZ), GermanyMetabolic plasticity and cancer stem cell dormancy in glioblastoma | |
| 17:20-17.50 | Oral presentations (3×10 min) | |
| 17.50–19:40 | Poster session part II | |
| 20:00-23:00 | Gala dinner (by invitation) |
CONFERENCE PROGRAM – DAY 3
FRIDAY, June 24, 2022
| 09:00–15:60 | Brain tumor pathobiology, diagnostics & therapy (chairs: Tika Benveniste, Sergiusz Nawrocki) |
|
| 09:00–9:35 | Itay Tirosh, Weizmann Institute of Science, Israel
Dissecting intra-tumor and inter-tumor heterogeneity in glioma |
|
| 09:35–10:10 | Rolf Bjerkvig, University of Bergen, Norway
Glioma cell invasion: growth patterns and mechanistic insight |
|
| 10:10–10:40 | Coffee break | |
| 10:40–11:15 | Guido Reifenberger, University of Dusseldorf, Germany
TBA |
|
| 11:15–11:50 | Maciej S. Lesniak, Northwestern University Feinberg School of Medicine, USA
Targeting HER2+ Breast Cancer Metastases in the Brain |
|
| 11:50–12:25 | Maria G. Castro, University of Michigan Medical School, USA
Epigenetic reprogramming of the tumor immune microenvironment in mutant IDH1 gliomas mediated myeloid cell populations and reverses immunosuppression |
|
| 12:25–13:25 | Lunch break | |
| 13:25–14:00 | Maciej Wiznerowicz, International Institute for Molecular Oncology, PolandCancer Stemness as Hallmark of Oncogenic De-differentiation | |
| 14:00–14:35 | Petra Hamerlik, Astrazeneca, UKFunctional interplay between aberrant DNA repair and cellular hierarchies in glioblastoma | |
| 14:35–15:10 | Agnieszka Bronisz, Mossakowski Medical Institute, Poland
Targeting hypoxia response for oncolytic virus immunotherapy |
|
| 15:10-15:45 | Waldemar Priebe, MD Anderson Cancer Center, University of Texas, Houston, USADrug discovery in academia: focus on CNS malignancies |
|
| 15:45-16:20 | Glenn Lesser, Wake Forest School of Medicine, USATBA | |
| 16:20–16.30 | Closing remarks | |
| 16.30–19:00 | Guided tour: Warsaw sightseeing |
